Combined operations deliver unified U.S. and European trial delivery, faster recruitment, and expanded evidence-generation capabilities across pharma, biotech, medtech, diagnostics, and digital health.

联合运营提供统一的美国和欧洲试验交付、更快的招募速度，并增强在制药、生物技术、医疗技术、诊断和数字健康领域的证据生成能力。

BOSTON

波士顿

,

，

Aug. 18, 2026

2026年8月18日

/PRNewswire/ -- Curavit Clinical Research, an innovative clinical research organization (CRO) and Remote Clinical Site, today announced the acquisition of the CRO assets of Lindus Health. This transaction follows Lindus shifting focus to developing its own pipeline of therapeutic assets, as Lindus Therapeutics.

/美通社/ -- 创新型临床研究组织（CRO）兼远程临床试验机构 Curavit Clinical Research 今日宣布收购 Lindus Health 的 CRO 资产。此次交易紧随 Lindus 将战略重心转向以 Lindus Therapeutics 名义开发其自有治疗产品管线之后。

This strategic move significantly expands Curavit's global footprint into Europe, providing life science sponsors with unified, end-to-end solutions for .

这一战略举措显著扩大了 Curavit 在欧洲的全球布局，为生命科学申办方提供统一的端到端解决方案。

decentralized

去中心化

, hybrid, and traditional clinical trials across both North America and Europe.

、混合型和传统临床试验，覆盖北美和欧洲地区。

The integration of Lindus Health's assets addresses the growing pressure on life science companies to reduce trial timelines and increase patient diversity while navigating complex international regulatory landscapes. Unlike fragmented regional niche providers or large, slow, legacy CROs, the combined organization offers a streamlined, agile partnership capable of executing complex multi-region studies.

林杜斯健康（Lindus Health）资产的整合，应对了生命科学公司在复杂国际监管环境中缩短临床试验周期、提高患者多样性所面临的日益增长的压力。与分散的区域性小众供应商或规模庞大但反应迟缓的传统合同研究组织（CRO）不同，合并后的组织能够提供精简、敏捷的合作伙伴关系，具备执行复杂多区域研究的能力。

Sponsors across pharma, biotech, medtech, and digital health now have access to accelerated global site activation, remote patient recruitment, and fit-for-purpose trial designs that match the pace of modern innovation..

制药、生物技术、医疗技术和数字健康领域的申办方现在能够获得加速的全球研究中心启动、远程患者招募以及契合现代创新节奏的适用性试验设计。

'Sponsors no longer have to choose between regional niche CROs or large, traditional providers when launching multi-country trials,' said Joel Morse, CEO and Co-Founder of Curavit. 'By combining Lindus' European clinical assets and team with Curavit's proven U.S. CRO, technology, and Remote Clinical Site infrastructure, we are offering sponsors a unified, alternative global solution.

“在启动多国临床试验时，申办方不再需要在区域性小众CRO与大型传统提供商之间做出选择，”Curavit首席执行官兼联合创始人Joel Morse表示。“通过将Lindus的欧洲临床资产和团队与Curavit久经验证的美国CRO服务、技术以及远程临床站点基础设施相结合，我们为申办方提供了一个统一的、替代性的全球解决方案。”

Life science sponsors can now recruit faster, reduce site burden, and run high-quality prospective trials across both North America and Europe under a single, agile operational partner.'.

生命科学申办方现在可以通过一个灵活单一的运营合作伙伴，加快受试者招募，减轻研究中心负担，并在北美和欧洲开展高质量的前瞻性临床试验。

With full-service CRO capabilities paired with dedicated Remote Clinical Site operations, Curavit is optimized to execute

凭借全方位的CRO服务能力，并结合专门的远程临床试验中心运营，Curavit得以优化执行

decentralized

去中心化的

, hybrid, and traditional clinical studies that lower trial costs, improve participant retention, and deliver clinical grade data across the U.S. and Europe.

、混合式和传统式临床研究，降低试验成本，提高受试者留存率，并在美国和欧洲提供符合临床级别的数据。

'We are pleased to partner with Curavit as the company enters its next phase of growth,' said Nate Lentz, Managing Partner at Osage Venture Partners and Curavit Board member. 'Clinical research is evolving rapidly, and sponsors increasingly need more flexible, technology-enabled approaches to generating clinical evidence.

“我们很高兴在Curavit进入下一增长阶段之际与其建立合作伙伴关系，”Osage Venture Partners的管理合伙人兼Curavit董事会成员Nate Lentz表示。“临床研究正在迅速发展，申办方越来越需要更灵活、技术赋能的方法来生成临床证据。

Curavit brings together deep clinical expertise, innovative trial models, and differentiated patient recruitment capabilities to help sponsors run trials faster and more efficiently. We believe Curavit is exceptionally well positioned to become a leader in the next generation of clinical research.'.

Curavit 汇聚深厚的临床经验、创新的试验模式以及差异化的患者招募能力，助力申办方更快速、高效地开展临床试验。我们相信，Curavit 具备卓越的优势，有望成为下一代临床研究的领导者。

Ready to accelerate your next clinical program? Curavit is standing by to help you accelerate your trials and improve participant retention with our expanded capabilities. Visit

准备好加速您的下一个临床项目了吗？Curavit 随时准备通过我们扩展的能力，帮助您加速试验并提高受试者保留率。访问

www.curavit.io

www.curavit.io

to explore our solutions or contact our clinical solutions team directly at

探索我们的解决方案，或直接通过以下方式联系我们的临床解决方案团队：

[email protected]

[email protected]

to schedule a consultation and discuss your upcoming study requirements.

安排咨询并讨论您即将进行的学习需求。

About Curavit

关于 Curavit

Curavit is a Next Generation CRO and Remote Clinical Site specializing in

Curavit 是一家专注于的下一代合同研究组织（CRO）和远程临床试验中心

decentralized

去中心化

and hybrid clinical trials, prospective real-world evidence (RWE) studies, and longitudinal participant engagement. The company partners with sponsors across therapeutics, diagnostics, medical devices, and digital health to deliver efficient, participant-centered clinical research programs across North America and Europe.

以及混合式临床试验、前瞻性真实世界证据（RWE）研究和纵向参与者参与。该公司与治疗、诊断、医疗器械和数字健康领域的赞助商合作，在北美和欧洲提供高效、以参与者为中心的临床研究项目。

For more information, visit .

更多信息，请访问。

www.curavit.io

www.curavit.io

.

。

SOURCE Curavit Clinical Research

来源：Curavit 临床研究

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示